WEST BRIDGEWATER, Mass. -- Boston Biomedica, Inc. announces that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its BBI Borrelia burgdorferi IgM and IgG Western Blot Test Kit. The test method separately detects IgM and IgG antibodies to B. burgdorferi, the infectious tickborne bacteria that cause Lyme Disease. The FDA's 510(k) clearance allows the test to be marketed and sold in the U.S. with the label 'For In Vitro Diagnostic Use'.
The BBI Borrelia burgdorferi IgM and IgG Western Blot Test Kit is intended for use in testing human serum samples that have been found positive or equivocal using a first-line test (enzyme immunoassay or immunofluorescence assay) for B. burgdorferi antibodies. The Western blot method identifies specific antibodies, and according to Centers for Disease Control and Prevention (CDC) guidelines, a supplementary test such as the Western blot should be used to provide additional information following a positive or equivocal result with the first-line Lyme test.
"This is the same test we developed and manufactured at our BBI Biotech Research Lab in the mid-1990s for use in our clinical laboratory," commented Dr. Patricia E. Garrett, BBI's senior vice president for science and technology. "When the clinical laboratory was sold, and our market research indicated a need for a high quality Western blot, we applied to the FDA for clearance using information we had collected in earlier clinical trials."
Kevin Quinlan, president and COO of BBI, said "We had several years of experience manufacturing and using this test in our own laboratory, and are pleased to be able to market it for in vitro diagnostic use. The market for the Lyme Western blot test includes hospital and clinical reference laboratories that our Accurun salespeople currently call on, so we have very cost-effectively added a product for this market."
BBI provides products and services to the diagnostics and life sciences industry to evaluate, monitor, and ensure the quality of infectious disease test results, to improve the preparation of specimens for genomic/proteomic testing, and to safely store and retrieve rare and valuable biological specimens.
Source: Boston Biomedica, Inc.
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.